Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

<p>Statistically Significant and Clinically Meaningful Increasein Primary Efficacy Endpoint at 24 Weeks of Treatment; Improvement Consistent Across All Prespecified Subgroups Statistically Significant and Clinically Meaningful Improvements in All Secondary Endpoints No Instances of Treatment Interruptions Due to Low LVEF Company to Host Conference Call and Webcast Today at 8:30 a.m. Eastern Time SOUTH SAN FRANCISCO, […]</p>
<p>The post <a href="https://forextv.com/top-news/cytokinetics-announces-positive-results-from-sequoia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-obstructive-hypertrophic-cardiomyopathy/">Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>